JP Morgan Chase
WHWK

JP Morgan Chase’s Whitehawk Therapeutics WHWK Stock Holding History

JP Morgan Chase’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$397 Hold
121
– – ﹤0.01% 7198
2025
Q4 		$293 Sell
121
-300
-71% -$688 ﹤0.01% 7123
2025
Q3 		$800 Hold
421
– – ﹤0.01% 7004
2025
Q2 		$787 Sell
421
-1,341
-76% -$2.33K ﹤0.01% 6647
2025
Q1 		$3.14K Buy
1,762
+284
+19% +$742 ﹤0.01% 6491
2024
Q4 		$4.66K Sell
1,478
-2,759
-65% -$6.25K ﹤0.01% 6527
2024
Q3 		$8.73K Buy
4,237
+3,816
+906% +$6.17K ﹤0.01% 6391
2024
Q2 		$615 Sell
421
-6,573
-94% -$12.2K ﹤0.01% 6669
2024
Q1 		$16.4K Sell
6,994
-3,554
-34% -$6.85K ﹤0.01% 6264
2023
Q4 		$21.3K Hold
10,548
– – ﹤0.01% 6237
2023
Q3 		$51.1K Sell
10,548
-2,814
-21% -$16.4K ﹤0.01% 5803
2023
Q2 		$91.4K Buy
13,362
+2,234
+20% +$17.4K ﹤0.01% 5507
2023
Q1 		$80K Buy
11,128
+2,896
+35% +$30.9K ﹤0.01% 5523
2022
Q4 		$105K Buy
8,232
+319
+4% +$4.17K ﹤0.01% 5339
2022
Q3 		$112K Buy
7,913
+171
+2% +$2.25K ﹤0.01% 5240
2022
Q2 		$95K Buy
+7,742
New +$115K ﹤0.01% 5435
2020
Q4 		– Sell
-427
Closed -$10K – 5992
2020
Q3 		$10K Buy
+427
New +$8.98K ﹤0.01% 5262
2019
Q2 		– Sell
-320
Closed -$4K – 6056
2019
Q1 		$4K Buy
+320
New +$13.8K ﹤0.01% 5638

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

JP Morgan Chase's WHWK Position: Q1 2026 in Review

JP Morgan Chase held its Whitehawk Therapeutics (WHWK) position steady in Q1 2026 at 121 shares worth $397. The position accounts for ﹤0.01% of the portfolio, ranked #7198.

JP Morgan Chase first reported a position in WHWK in Q1 2019 and has held it in 18 quarters since. The position peaked at $112K in Q3 2022. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • JP Morgan Chase held 121 shares of Whitehawk Therapeutics worth $397 as of Q1 2026.
  • JP Morgan Chase left its Whitehawk Therapeutics share count unchanged in Q1 2026.
  • Whitehawk Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7198 holding.
  • JP Morgan Chase first reported a position in Whitehawk Therapeutics in Q1 2019 and has held it in 18 quarters since.
  • JP Morgan Chase's Whitehawk Therapeutics position peaked at $112K in Q3 2022.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.